Heyholder
‹ Activism Filings

SAMIL PHARMACEUTICAL CO.,LTD Q3 revenue KRW 51.4 billion, operating loss of KRW 3.19 billion

SAMIL PHARMACEUTICAL CO.,LTD· Periodic Report

AI summary · Not investment advice

Samil Pharmaceutical sold KRW 51.4 billion in Q3 and lost KRW 3.19 billion from its main business, versus sales of KRW 51.2 billion and a loss of KRW 5.15 billion a year earlier.

Operating profit · 3 months

KRW -3.2 billion

Key facts

Revenue (3 months)
KRW 51.4 billion
Net income (3 months)
KRW -6.4 billion
Period
Q3 (cumulative Jan 1, 2026 ~ Sep 30, 2026)
Revenue (prior-year 3 months)
KRW 51.2 billion
Revenue (year to date)
KRW 154.6 billion
Operating profit (prior-year 3 months)
KRW -5.2 billion
Operating profit (year to date)
KRW -17.9 billion
Net income (prior-year 3 months)
KRW -7.9 billion
Net income (year to date)
KRW -24.9 billion

Commentary

AI commentary · Not investment advice

What happened

Samil Pharmaceutical filed its quarterly report for the 3rd quarter, on a consolidated basis. Sales for the latest 3 months were KRW 51.42 billion. That is 0.5% above the same period a year earlier and 1.6% above the previous quarter.

In the company's terms

Operating profit (profit from the core business) for the latest 3 months was a loss of KRW 3.19 billion. A year earlier, the 3-month operating loss was KRW 5.15 billion. Net income for the latest 3 months was a loss of KRW 6.40 billion. A year earlier, the 3-month net loss was KRW 7.93 billion.

What changes for shareholders

For the year to date (January 1 to September 30), sales were KRW 154.57 billion. The operating loss was KRW 17.90 billion. The net loss was KRW 24.92 billion.

Comments

No comments yet

Comments from shareholders will appear here.